Evaluation of the Influence of Irritable Bowel Syndrome on the Severity of Liver Fibrosis in Patients with Chronic Persistent Hepatitis
Objective. The study is focused on exploring the relationship between irritable bowel syndrome (IBS) and the development of liver fibrosis in patients with chronic persistent hepatitis, as well as evaluating the role of IBS as a potential factor in the progression of this disease. Materials and Methods. We examined 69 patients aged 18–59 years, including 36 men (52 %) and 33 women (48 %), with chronic persistent hepatitis (CPH). The patients were divided into two groups: Group 1, 35 patients with CPH combined with irritable bowel syndrome (IBS); Group 2, 34 patients with CPH without IBS. The instrumental methods used for the study included ultrasound diagnostics of the abdominal organs. To achieve the study's objectives, the degree of liver fibrosis was determined using transient elastography with the LFP-5 transducer of the Mindray Hepatus 6 ultrasound system. Fibrosis was assessed using the METAVIR scale. Results. The study revealed a statistically significant pattern: patients with chronic hepatic pulmonary disease (CHP) combined with IBS significantly more often exhibited more pronounced pathological changes in the hepatobiliary system. The ultrasound detection rate of liver damage in patients with comorbid pathology (CHP + IBS) was 1.9 times higher than in patients with isolated CHP. Conclusions. The presence of comorbid pathology in the form of irritable bowel syndrome in patients with chronic persistent hepatitis can serve as a marker of an increased risk of liver disease progression and requires more careful monitoring using instrumental methods, primarily ultrasound, for the timely diagnosis of complications.
Gridnev V.I., Sotskaya Y.A. 2026. Evaluation of the Influence of Irritable Bowel Syndrome
on the Severity of Liver Fibrosis in Patients with Chronic Persistent Hepatitis. Challenges in Modern Medicine, 49(2): 121–130 (in Russian). DOI: 10.52575/2687-0940-2026-49-2-121-130. EDN: YNMTVA
While nobody left any comments to this publication.
You can be first.
Список литературы
Голованова Е.В. 2021. Как повысить эффективность лечения больных с синдромом раздраженного кишечника? Медицинский Совет. (5): 134–140. https://doi.org/10.21518/2079-701X-2021-5-134-140
Жирков И.И., Гордиенко А.В., Павлович И.М., Голофеевский В.Ю., Маковеева О.В. 2020. Неинвазивные методы диагностики стеатоза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 174(5): 61–66. https://doi.org/10.31146/1682-8658-ecg-177-5-61-66
Здравоохранение в России. 2025: Стат. сб./ Росстат. М., 2025. 149. URL: https://www.rosstat.gov.ru/storage/mediabank/Zdravooxran_2025.pdf (дата обращения: 05.04.2026)
Минушкин ОН. 2023. Синдром раздраженного кишечника и СРК-подобный синдром: современные представления, диагностика, лечебные подходы. Медицинский Совет. (13): 96–101. https://doi.org/10.21518/ms2022-058
Пахомова И.Г. 2023. Болевой абдоминальный синдром у пациентов с синдромом раздраженного кишечника: особенности подбора терапии. Медицинский Совет. (18): 101–107. https://doi.org/10.21518/ms2023-360
Соловьева Ю.А. 2020. Неинвазивные методы диагностики фиброза печени. Вестник Северо-Восточного федерального университета имени М.К. Аммосова. Vestnik of North-Eastern Federal University. Серия «Медицинские науки. Medical Sciences». (4): 45–54. https://doi.org/10.25587/SVFU.2020.21.4.005
Abi-Aad S.J., Lovell M., Khalaf R.T., Sokol R.J. 2025. Pathogenesis and Management of Intestinal Failure-Associated Liver Disease. Seminars in liver disease. 45(1): 66–80. https://doi.org/10.1055/a-2545-7370
Anis M.A., Shahid Y., Majeed A.A., Abid S. 2025. Microbiome and Gut-Liver Interactions: From Mechanisms to Therapies. World Journal of Gastroenterology. 31(40): 111409. https://doi.org/10.3748/wjg.v31.i40.111409
Cheng Z., Yang L., Chu H. 2025. The Role of Gut Microbiota, Exosomes, and their Interaction in the PATHOGENESIS of ALD. Journal of Advanced Research. 72: 353–367. https://doi.org/10.1016/j.jare.2024.07.002
Costa C.F.F.A., Sampaio-Maia B., Araujo R., Nascimento D.S., Ferreira-Gomes J., Pestana M., Azevedo M.J., Alencastre I.S. 2022. Gut Microbiome and Organ Fibrosis. Nutrients. 14(2): 352. https://doi.org/10.3390/nu14020352
Cui C., Gao S., Shi J., Wang K. 2025. Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. Gut and Liver. 19(4): 479–507. https://doi.org/10.5009/gnl240539
Gudan A., Jamioł-Milc D., Hawryłkowicz V., Skonieczna-Żydecka K., Stachowska E. 2022. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients. 14(24): 5261. https://doi.org/10.3390/nu14245261
Laivacuma S., Oblate O., Derovs A. 2025. Gut Microbiota and the Gut-Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies. Microorganisms. 13(5): 1053. https://doi.org/10.3390/microorganisms13051053
Liu S., Yang X. 2023. Intestinal Flora Plays a Role in the Progression of Hepatitis-Cirrhosis-Liver Cancer. Frontiers in Cellular and Infection Microbiology. 13: 1140126. https://doi.org/10.3389/fcimb.2023.1140126
Schnabl B., Damman C.J., Carr R.M. 2025. Metabolic Dysfunction-Associated Steatotic Liver Disease and the Gut Microbiome: Pathogenic Insights and Therapeutic Innovations. The Journal of Clinical Investigation. 135(7): e186423. https://doi.org/10.1172/JCI186423
Shu W., Shanjian C., Jinpiao L., Qishui O. 2022. Gut Microbiota Dysbiosis in Patients with Hepatitis B Virus-Related Cirrhosis. Annals of hepatology. 27(2): 100676. https://doi.org/10.1016/j.aohep.2022.100676
Simon E., Călinoiu L.F., Mitrea L., Vodnar D.C. 2021. Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome. Nutrients. 13(6): 2112. https://doi.org/10.3390/nu13062112
Smith M.L., Wade J.B., Wolstenholme J., Bajaj J.S. 2024. Gut Microbiome-Brain-Cirrhosis Axis. Hepatology (Baltimore, Md.). 80(2): 465–485. https://doi.org/10.1097/HEP.0000000000000344
Tilg H., Adolph T.E., Trauner M. 2022. Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications. Cell Metabolism. 34(11): 1700–1718. https://doi.org/10.1016/j.cmet.2022.09.017
Wang Y., Bai Z., Sun J., Gong Q., Miao W., Niu Z., Li X., Xu J., Lai Z. 2025. Intestinal Congestion-Driven Gut Dysbiosis: A Cross-Disease Hemodynamic Mechanism in Liver Cirrhosis and Heart Failure. Journal of Translational Medicine. 24(1): 79. https://doi.org/10.1186/s12967-025-07547-3
Yan Y., Zeng J., Xing L., Li C. 2021. Extra- and Intra-Cellular Mechanisms of Hepatic Stellate Cell Activation. Biomedicines. 9(8): 1014. https://doi.org/10.3390/biomedicines9081014
References
Golovanova E.V. 2021. How to Improve Effectiveness of Treatment of Patients with Irritable Bowel Syndrome? Meditsinskiy sovet = Medical Council. (5): 134–140 (in Russian). https://doi.org/10.21518/2079-701X-2021-5-134-140
Zhirkov I.I., Gordienko A.V., Pavlovich I.M., Golofeevsky V.Yu., Makoveeva O.V. 2020. Noninvasive Methods of Diagnosis of Steatosis in Non-Alcoholic Fatty Liver Disease. Experimental and Clinical Gastroenterology. 174(5): 61–66 (in Russian). https://doi.org/10.31146/1682-8658-ecg-177-5-61-66
Healthcare in Russia. 2025: Stat.sb./ Rosstat. M., 2025. 149. URL: https://www.rosstat.gov.ru/storage/mediabank/Zdravooxran_2025.pdf (date of access: 05.04.2026).
Minushkin O.N. 2023. Irritable Bowel Syndrome and IBS-like Syndrome: Current Concepts, Diagnosis, Treatment Approaches. Meditsinskiy sovet = Medical Council. (13): 96–101 (in Russian). https://doi.org/10.21518/ms2022-058
Pakhomova I.G. 2023. Abdominal Pain Syndrome in Patients with Irritable Bowel Syndrome: Features of Selection of Therapy. Meditsinskiy sovet = Medical Council. (18): 101–107 (in Russian). https://doi.org/10.21518/ms2023-360
Soloveva Y.A. 2020. Non-Invasive Diagnosis of Liver Fibrosis. Vestnik of North-Eastern Federal University. Medical Sciences. (4): 45–54. https://doi.org/10.25587/SVFU.2020.21.4.005
Abi-Aad S.J., Lovell M., Khalaf R.T., Sokol R.J. 2025. Pathogenesis and Management of Intestinal Failure-Associated Liver Disease. Seminars in liver disease. 45(1): 66–80. https://doi.org/10.1055/a-2545-7370
Anis M.A., Shahid Y., Majeed A.A., Abid S. 2025. Microbiome and Gut-Liver Interactions: From Mechanisms to Therapies. World Journal of Gastroenterology. 31(40): 111409. https://doi.org/10.3748/wjg.v31.i40.111409
Cheng Z., Yang L., Chu H. 2025. The Role of Gut Microbiota, Exosomes, and their Interaction in the PATHOGENESIS of ALD. Journal of Advanced Research. 72: 353–367. https://doi.org/10.1016/j.jare.2024.07.002
Costa C.F.F.A., Sampaio-Maia B., Araujo R., Nascimento D.S., Ferreira-Gomes J., Pestana M., Azevedo M.J., Alencastre I.S. 2022. Gut Microbiome and Organ Fibrosis. Nutrients. 14(2): 352. https://doi.org/10.3390/nu14020352
Cui C., Gao S., Shi J., Wang K. 2025. Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. Gut and Liver. 19(4): 479–507. https://doi.org/10.5009/gnl240539
Gudan A., Jamioł-Milc D., Hawryłkowicz V., Skonieczna-Żydecka K., Stachowska E. 2022. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients. 14(24): 5261. https://doi.org/10.3390/nu14245261
Laivacuma S., Oblate O., Derovs A. 2025. Gut Microbiota and the Gut-Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies. Microorganisms. 13(5): 1053. https://doi.org/10.3390/microorganisms13051053
Liu S., Yang X. 2023. Intestinal Flora Plays a Role in the Progression of Hepatitis-Cirrhosis-Liver Cancer. Frontiers in Cellular and Infection Microbiology. 13: 1140126. https://doi.org/10.3389/fcimb.2023.1140126
Schnabl B., Damman C.J., Carr R.M. 2025. Metabolic Dysfunction-Associated Steatotic Liver Disease and the Gut Microbiome: Pathogenic Insights and Therapeutic Innovations. The Journal of Clinical Investigation. 135(7): e186423. https://doi.org/10.1172/JCI186423
Shu W., Shanjian C., Jinpiao L., Qishui O. 2022. Gut Microbiota Dysbiosis in Patients with Hepatitis B Virus-Related Cirrhosis. Annals of hepatology. 27(2): 100676. https://doi.org/10.1016/j.aohep.2022.100676
Simon E., Călinoiu L.F., Mitrea L., Vodnar D.C. 2021. Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome. Nutrients. 13(6): 2112. https://doi.org/10.3390/nu13062112
Smith M.L., Wade J.B., Wolstenholme J., Bajaj J.S. 2024. Gut Microbiome-Brain-Cirrhosis Axis. Hepatology (Baltimore, Md.). 80(2): 465–485. https://doi.org/10.1097/HEP.0000000000000344
Tilg H., Adolph T.E., Trauner M. 2022. Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications. Cell Metabolism. 34(11): 1700–1718. https://doi.org/10.1016/j.cmet.2022.09.017
Wang Y., Bai Z., Sun J., Gong Q., Miao W., Niu Z., Li X., Xu J., Lai Z. 2025. Intestinal Congestion-Driven Gut Dysbiosis: A Cross-Disease Hemodynamic Mechanism in Liver Cirrhosis and Heart Failure. Journal of Translational Medicine. 24(1): 79. https://doi.org/10.1186/s12967-025-07547-3
Yan Y., Zeng J., Xing L., Li C. 2021. Extra- and Intra-Cellular Mechanisms of Hepatic Stellate Cell Activation. Biomedicines. 9(8): 1014. https://doi.org/10.3390/biomedicines9081014